孟鲁司特联合布地奈德福莫特罗治疗慢性喘息性支气管炎的临床观察

目的:观察孟鲁司特联合布地奈德福莫特罗对慢性喘息性支气管炎的疗效.方法:将68例病例随机分为观察组和对照组,每组各34例.对照组给予常规抗炎、解痉、祛痰以及布地奈德福莫特罗(信必可都保)吸入治疗,观察组在对照组治疗基础上加用孟鲁司特(顺耳宁)10 mg,每晚睡前1次;疗程均为14 d,分别于疗程结束后评价疗效,并对比治疗前和治疗后第14天肺功能第1秒用力呼气量占预计值百分比(FEV1％)、用力肺活量(FVC)、呼气流速峰值(PEF),记录出院1年内再住院率.结果:总有效率观察组为91.18％,对照组为76.47％,2组比较有显著性差异(P＜0.05);观察组肺功能FEV1％、FVC、PEF明显

Effects of Inhaled Oral Montelukast Combined with Budesonide/Formoterol in Treatment of Patients with Chronic Asthmatic Bronchitis

Objective:To investigate the efficacy of inhaled oral montelukast(singulair) combined with budesonide/formoterol(symbicort) in treatment of patients with chronic asthmatic bronchitis.Methods:68 cases with chronica sthmatic bronchitis were randomly divided into two groups,in the control group was given conventional anti-inflammatory,antispasmodic,expectorant and budesonide/formoterol(symbicort)inhalation treatment,the case of treatment group were treated based on the control group treatment and additional oral montelukast(singulair) 10 mg every night before bed time;course of 14 days.After the treatment,evaluation of clinical efficacy in 2 groups respectively,and tested the lung function’s FEV1%,FVC,PEF before and after treatment in 14th day,compared them,and recorded the hospital readmission rate for one year.Results:the total effective of treatment group(91.18%),and the total efficiency of control group(76.47%),there was statistically significant difference(P<0.05);treatment group lung function FEV1%,FVC,PEF improved significantly better than the control group.One year readmission rate of treatment group was significantly less than control group.Conclusion:Montelukast combined with budesonide/formoterol,is significantly better than budesonide,formoterol(symbicort) for chronic asthmatic bronchitis,it should be promoted.